Invesco’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Invesco’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-1,935	Closed	-$11K	–	3822
2016 Q1	$11K	Sell	1,935 -147	-7%	-$1.91K	﹤0.01%	3697
2015 Q4	$36K	Buy	2,082 +99	+5%	+$2.36K	﹤0.01%	3720
2015 Q3	$42K	Buy	1,983 +23	+1%	+$788	﹤0.01%	3747
2015 Q2	$97K	Buy	+1,960	New	+$117K	﹤0.01%	3860
2014 Q1	–	Sell	-211	Closed	-$12K	–	4480
2013 Q4	$12K	Sell	211 -24,576	-99%	-$1.38M	﹤0.01%	4199
2013 Q3	$1.52M	Buy	24,787 +16,314	+193%	+$1.1M	﹤0.01%	2740
2013 Q2	$495K	Buy	+8,473	New	+$521K	﹤0.01%	3281

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

TAM

Tiverton Asset Management Wilimington, Delaware $2.88B AUM 5.6% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco's OREX Position: Q2 2016 in Review

Invesco sold out of Orexigen Therapeutics, Inc. (OREX) in Q2 2016, closing a stake of 1,935 shares — an estimated $11K sold.

Invesco first reported a position in OREX in Q2 2013 and held it in 7 quarters. The position peaked at $1.52M in Q3 2013. 73 funds tracked by Wall St. Rank hold OREX as of Q2 2016.

Invesco reported no remaining Orexigen Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
Invesco sold 1,935 Orexigen Therapeutics, Inc. shares in Q2 2016, an estimated $11K.
Invesco first reported a position in Orexigen Therapeutics, Inc. in Q2 2013 and held it in 7 quarters.
Invesco's Orexigen Therapeutics, Inc. position peaked at $1.52M in Q3 2013.
73 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q2 2016.

Based on Invesco's 13F filing for Q2 2016, filed 15 Aug 2016.